OTC Markets OTCQB - Delayed Quote USD

Zeo ScientifiX, Inc. (ZEOX)

1.9900
+0.0400
+(2.05%)
As of 9:37:00 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
10/31/2024
10/31/2023
10/31/2022
10/31/2021
Total Revenue
4,556
4,620
4,558
6,491.0080
5,597.4870
Cost of Revenue
876
844
508
753.5340
547.8810
Gross Profit
3,680
3,776
4,050
5,737.4740
5,049.6060
Operating Expense
9,090
9,095
10,818
14,580.4340
17,793.7090
Operating Income
-5,410
-5,319
-6,768
-8,842.9600
-12,744.1030
Net Non Operating Interest Income Expense
-87
-92
-431
-398.2600
-37.9340
Other Income Expense
589
706
212
344.6630
25.4770
Pretax Income
-4,908
-4,705
-6,987
-8,896.5570
-12,756.5600
Tax Provision
--
--
--
0
0
Net Income Common Stockholders
-4,908
-4,705
-6,987
-8,896.5570
-12,756.5600
Diluted NI Available to Com Stockholders
-4,908
-4,705
-6,987
-8,896.5570
-12,756.5600
Basic EPS
-0.77
-0.74
-0.99
-1.56
-2.00
Diluted EPS
-0.77
-0.74
-0.99
-1.56
-2.00
Basic Average Shares
6,374.8980
6,336.3920
7,028.6380
5,688.2300
5,297.4410
Diluted Average Shares
6,374.8980
6,336.3920
7,028.6380
5,688.2300
5,297.4410
Total Operating Income as Reported
-5,410
-5,319
-6,768
-8,842.9600
-12,744.1030
Total Expenses
9,966
9,939
11,326
15,333.9680
18,341.5900
Net Income from Continuing & Discontinued Operation
-4,908
-4,705
-6,987
-8,896.5570
-12,756.5600
Normalized Income
-5,236
-5,146
-7,228
-8,896.5570
-12,756.5600
Interest Expense
87
92
431
398.2600
37.9340
Net Interest Income
-87
-92
-431
-398.2600
-37.9340
EBIT
-4,821
-4,613
-6,556
-8,498.2970
-12,718.6260
EBITDA
-4,748
-4,539
-6,070
-8,165.7890
-12,665.9240
Reconciled Cost of Revenue
876
844
508
753.5340
547.8810
Reconciled Depreciation
73
74
486
332.5080
52.7020
Net Income from Continuing Operation Net Minority Interest
-4,908
-4,705
-6,987
-8,896.5570
-12,756.5600
Total Unusual Items Excluding Goodwill
328
441
241
0
--
Total Unusual Items
328
441
241
0
--
Normalized EBITDA
-5,076
-4,980
-6,311
-8,165.7890
-12,665.9240
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
10/31/2021 - 3/1/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BIXT Bioxytran, Inc.
0.1300
0.00%
 
THAR Tharimmune, Inc.
1.5999
+5.96%
 
RNAC Cartesian Therapeutics, Inc.
10.81
-2.04%
 
ENVB Enveric Biosciences, Inc.
1.3100
-0.55%
 
CELU Celularity Inc.
2.0300
-2.40%
 
QNRX Quoin Pharmaceuticals, Ltd.
8.46
-4.89%
 
BCLI Brainstorm Cell Therapeutics Inc.
1.2300
+0.82%
 
HEPA Hepion Pharmaceuticals, Inc.
0.0603
+5.60%
 
GNPX Genprex, Inc.
0.3151
+12.46%
 
ATRA Atara Biotherapeutics, Inc.
9.34
+1.52%